Carregant...
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
In the past decade, recombinant vectors based on a non-pathogenic parvovirus, the adeno-associated virus (AAV), have taken center stage as a gene delivery vehicle for the potential gene therapy for a number of human diseases. To date, the safety of AAV vectors in 176 phase I, II, and III clinical tr...
Guardat en:
| Publicat a: | Mol Ther Methods Clin Dev |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Gene & Cell Therapy
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6378346/ https://ncbi.nlm.nih.gov/pubmed/30815511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2019.01.008 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|